Why the study?
Does atriopeptin III affect the lumen diameter of isolated rat afferent and efferent arterioles?
Does atriopeptin III affect the lumen diameter of isolated rat afferent and efferent arterioles?
Atriopeptin III exhibits differential vasoactive effects on renal microvasculature, dilating preconstricted afferent arterioles while constricting efferent arterioles.
Answers are grounded in this paper and cite their sources.
Should not yet change practice; leaves open net glomerular hemodynamic effects in vivo.
The effects of atriopeptin III (AP III) on in vitro prepared afferent (AA) and efferent arterioles (EA) from rat kidneys were tested in a system in which lumen diameter could be measured. AP III (10(-13)-10(-7) M) had no effect on lumen diameter of AA that were not preconstricted. When AA were preconstricted with either angiotensin II (ANG II) or norepinephrine (NE), however, AP III increased lumen diameter in a concentration-dependent manner to the preconstriction baseline value. Maximal vasodilation occurred at 10(-10) M AP III. Unlike AA, EA constricted by 50% to 10(-10) M AP III further constricted EA that were pretreated with ANG II or NE. Dilation in ANG II-preconstricted AA to AP III was not inhibited by indomethacin. Constriction of EA to AP III was not altered by [Sar1-Ala8] ANG II, enalapril, OKY 046, or phentolamine. Results indicate that in isolated renal arterioles AP III dilates preconstricted AA but constricts EA that have either not been pretreated or have been preconstricted with other agonists. The effect of AP III on preconstricted AA does not require vasodilator prostaglandin mediation. The constrictor effect of AP III on EA is not dependent on angiotensin, thromboxane, or alpha-adrenergic mediation.
No takes yet. Share an insight, caveat, or question.
Lanese et al. (1991) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: